Entry Inhibitors in Development

ARV Pipeline: Dolutegravir, TAF (GS-7340), MK-1439 and Cenicriviroc (March/April 2013)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
CCR5/CCR2 Antagonist Cenicriviroc: 24-Week Data vs. Efavirenz in ART-Naive (March 8, 2013)
From National AIDS Treatment Advocacy Project
New Drug Hits HIV and Inflammatory Processes (March 7, 2013)
From MedPage Today
New Antiretroviral Agents: Cenicriviroc (Video) (March 7, 2013)
From HIVandHepatitis.com
New HIV Drug Cenicriviroc Shows Non-Inferiority to Efavirenz and Activity Against Inflammation, Study Finds (March 6, 2013)
In The 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013), from TheBodyPRO.com
Dual CCR5/CCR2 Inhibitor Cenicriviroc Has Both Anti-HIV and Anti-Inflammatory Effects (March 4, 2013)
From HIVandHepatitis.com
Long-Acting Drug in Development (November/December 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
Study Summaries From ICAAC 2012 (September/October 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
Once-Weekly and Once-Monthly HIV Meds in the Pipeline: Studies From ICAAC 2012 (September 17, 2012)
In The 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012), from TheBodyPRO.com
New Long-Acting HIV Fusion Inhibitor Albuvirtide Looks Promising in Early Studies (September 11, 2012)
From HIVandHepatitis.com

VIEW ALL ARTICLES

MOST VIEWED ARTICLES

	HIV Management Today: Mental Health & HIV, the Uncharted Territory
	Danish Study Targets HIV Reservoir, in Latest Search for HIV Cure
	10 Top Studies Whose Impact Will Last Well Beyond CROI 2013
	CROI 2013: Women's Issues in HIV Research (Video)
	HIV Opportunistic Infection Guidelines Updated
	PrEP Failures and Successes: One Study Whose Impact Will Last Well Beyond CROI 2013

More Most Viewed Articles

TheBodyPRO.com is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. TheBodyPRO.com and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBodyPRO.com's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBodyPRO.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBodyPRO.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.